Caring Brands, Inc. (NASDAQ:CABR) Sees Large Decrease in Short Interest

Caring Brands, Inc. (NASDAQ:CABR) saw a significant drop in short interest in the month of April. As of April 30th, there was short interest totaling 18,964 shares, a drop of 45.7% from the April 15th total of 34,917 shares. Based on an average daily volume of 53,861 shares, the days-to-cover ratio is currently 0.4 days. Approximately 0.2% of the shares of the company are sold short.

Analysts Set New Price Targets

Separately, Weiss Ratings started coverage on shares of Caring Brands in a report on Monday, January 26th. They set a “sell (e)” rating on the stock. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Caring Brands Price Performance

NASDAQ:CABR traded down $0.04 during mid-day trading on Friday, reaching $0.94. The stock had a trading volume of 118,400 shares, compared to its average volume of 73,406. The business has a 50-day simple moving average of $1.04. The stock has a market capitalization of $8.54 million and a PE ratio of -2.54. The company has a quick ratio of 13.09, a current ratio of 5.66 and a debt-to-equity ratio of 0.03. Caring Brands has a 12 month low of $0.71 and a 12 month high of $5.35.

Caring Brands (NASDAQ:CABR) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.27) earnings per share (EPS) for the quarter.

Institutional Trading of Caring Brands

A hedge fund recently bought a new stake in Caring Brands stock. Jane Street Group LLC bought a new stake in Caring Brands, Inc. (NASDAQ:CABR) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 34,446 shares of the company’s stock, valued at approximately $30,000. Jane Street Group LLC owned approximately 0.25% of Caring Brands at the end of the most recent reporting period.

About Caring Brands

We are a wellness consumer products company. We offer several over-the-counter, or (OTC) and cosmetic, consumer products. Our method of operation is to ensure that (1) the mechanism of action of all products is established, (2) efficacy is determined through controlled clinical trials, (3) products are protected by issued and filed patents, and (4) products have acceptable commercial stability. Prior to its Q3 2022 commercial launch in India as a treatment for vitiligo and psoriasis, Photocil was briefly launched in the United States markets from December 2022 until February 2023, however, was subsequently removed from the market due to insufficient sales resulting from the lack of a dedicated sales and marketing team.